x-tole2

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026 14:00 ET | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE)…

1 day ago